

**GENE ABERRATIONS AND METHYLATION
ANALYSIS OF JAK/STAT AND TOLL-LIKE
RECEPTOR DOWNSTREAM SIGNALLING IN
BCR-ABL-NEGATIVE MYELOPROLIFERATIVE
NEOPLASMS AND MYELOYDYSPLASTIC
SYNDROME/MYELOPROLIFERATIVE
NEOPLASMS OVERLAP SYNDROMES**

CHIA YUH CAI

UNIVERSITI SAINS MALAYSIA

2021

**GENE ABERRATIONS AND METHYLATION
ANALYSIS OF JAK/STAT AND TOLL-LIKE
RECEPTOR DOWNSTREAM SIGNALLING IN
BCR-ABL-NEGATIVE MYELOPROLIFERATIVE
NEOPLASMS (MPN) AND MYELOYDYSPLASTIC
SYNDROME/MYELOPROLIFERATIVE
NEOPLASMS OVERLAP SYNDROMES**

by

CHIA YUH CAI

**Thesis submitted in fulfilment of the requirements
for the degree of
Master of Science**

OCTOBER 2021

ACKNOWLEDGEMENT

First of all, I would like to use this opportunity to express my gratitude and thanks to my honourable supervisor, Dr Marini Ramli for her supervision, continuous guidance, advice and support throughout my study. I am also sincerely grateful to my co-supervisors, Associate Professor Dr Muhammad Farid Johan, Professor Dr Rosline Hassan and Dr Md Asiful Islam for assisting in solving problems and helping me in gaining new knowledge. This study project would not have been completed without all my supervisors.

Most grateful to the School of Medical Sciences, Universiti Sains Malaysia (USM) for all the support and facilities provided to perform this study. Many thanks to all staff at the Laboratory of Molecular Biology, Central Research Laboratory (CRL), especially Puan Abdah Karimah Che Md Nor, Encik Zulkefli Sanip and Puan Afzan Hawani Alias for their patience, teaching and helping me in polishing my skill in lab techniques. I am also grateful to the staff at Haematology Laboratory, Hospital USM and Institute for Research in Molecular Medicine (INFORMM). Many sincere thanks also go to all academic lecturers, staff and postgraduate students in Haematology Department, USM who offered me considerable help and advice and thank you for all the unforgettable experiences and memories.

I would like to take this opportunity to record my deepest appreciation and thanks to my parents and siblings for their endless love and support. I am also grateful to the Division of Research and Innovation, USM and Ministry of Higher Education, Malaysia for financial assistance to continue my higher study. Last but not least, I am thankful to USM for awarding the RUI grant (1001/PPSP/812187) for a financial grant which enabled me to conduct and complete this study successfully.

TABLE OF CONTENTS

| | |
|--|---------------|
| ACKNOWLEDGEMENT | ii |
| TABLE OF CONTENTS | iii |
| LIST OF TABLES | xi |
| LIST OF FIGURES | xv |
| LIST OF ABBREVIATIONS | xxii |
| LIST OF APPENDICES | xxvii |
| ABSTRAK | xxviii |
| ABSTRACT | xxx |
| CHAPTER 1 INTRODUCTION | 1 |
| 1.1 Introduction to the study | 1 |
| 1.2 Statement of the problem | 6 |
| 1.3 Research question..... | 8 |
| 1.4 Justification of the study | 8 |
| 1.5 Hypothesis | 9 |
| 1.6 Objective of the study | 9 |
| 1.6.1 General objective..... | 9 |
| 1.6.2 Specific objectives..... | 9 |
| CHAPTER 2 LITERATURE REVIEW | 11 |
| 2.1 Myeloproliferative neoplasms (MPN) | 11 |
| 2.1.1 <i>BCR-ABL</i> -negative MPN | 11 |
| 2.1.1(a) Polycythaemia vera (PV)..... | 12 |
| 2.1.1(b) Essential thrombocythaemia (ET) | 13 |
| 2.1.1(c) Myelofibrosis | 15 |
| 2.2 Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) overlap syndromes..... | 18 |

| | | |
|----------|--|----|
| 2.2.1 | Chronic myelomonocytic leukaemia (CMML)..... | 19 |
| 2.2.2 | Atypical chronic myeloid leukaemia (aCML) | 21 |
| 2.2.3 | Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) | 23 |
| 2.2.4 | Juvenile myelomonocytic leukaemia (JMML) | 25 |
| 2.2.5 | MDS/MPN-unclassifiable (MDS/MPN-U)..... | 27 |
| 2.3 | Janus kinase/signal transducers and activators of transcription (JAK/STAT)..... | 27 |
| 2.3.1 | Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling pathway | 27 |
| 2.3.2 | Janus kinase 2 (<i>JAK2</i>) gene..... | 28 |
| 2.3.2(a) | Structure of the <i>JAK2</i> gene | 29 |
| 2.3.2(b) | Roles of the <i>JAK2</i> gene..... | 30 |
| 2.3.2(c) | <i>JAK2</i> V617F mutation in <i>BCR-ABL</i> -negative MPN | 31 |
| 2.3.2(d) | <i>JAK2</i> V617F mutation in MDS/MPN..... | 32 |
| 2.3.2(e) | <i>JAK2</i> exon 12 mutations in <i>BCR-ABL</i> -negative MPN..... | 32 |
| 2.3.2(f) | <i>JAK2</i> exon 12 mutations in MDS/MPN | 33 |
| 2.3.3 | Ten-eleven translocation 2 (<i>TET2</i>) gene | 33 |
| 2.3.3(a) | Structure of the <i>TET2</i> gene | 34 |
| 2.3.3(b) | Roles of the <i>TET2</i> gene..... | 34 |
| 2.3.3(c) | <i>TET2</i> mutations in <i>BCR-ABL</i> -negative MPN | 36 |
| 2.3.3(d) | <i>TET2</i> mutations in MDS/MPN | 37 |
| 2.3.4 | Suppressor of cytokine signalling proteins 3 (<i>SOCS3</i>) gene..... | 38 |
| 2.3.4(a) | Structure of <i>SOCS3</i> gene | 38 |
| 2.3.4(b) | Roles of <i>SOCS3</i> gene..... | 39 |
| 2.3.4(c) | Methylation profile of <i>SOCS3</i> gene in <i>BCR-ABL</i> - negative MPN | 40 |
| 2.3.4(d) | Methylation profile of <i>SOCS3</i> gene in MDS/MPN | 41 |
| 2.4 | Toll-like receptors (TLR) | 41 |

| | | |
|-----------------------------------|---|-----------|
| 2.4.1 | Toll-like receptors (TLR) signalling pathway..... | 41 |
| 2.4.2 | Myeloid differentiation primary response 88 (<i>MyD88</i>) gene..... | 43 |
| 2.4.2(a) | Structure of the <i>MyD88</i> gene..... | 43 |
| 2.4.2(b) | Roles of the <i>MyD88</i> gene | 44 |
| 2.4.2(c) | <i>MyD88</i> mutations in blood malignancies | 45 |
| 2.4.3 | Inositol polyphosphate-5-phosphatase D (<i>INPP5D</i>) gene | 46 |
| 2.4.3(a) | Structure of <i>INPP5D</i> gene..... | 46 |
| 2.4.3(b) | Roles of <i>INPP5D</i> gene..... | 47 |
| 2.4.3(c) | Methylation profile of <i>INPP5D</i> gene in <i>BCR-ABL</i> - negative MPN | 48 |
| 2.4.3(d) | Methylation profile of <i>INPP5D</i> gene in MDS/MPN..... | 48 |
| 2.5 | Crosstalk among JAK/STAT and TLR signalling pathways | 48 |
| 2.6 | Methods for detecting mutation and methylation | 50 |
| 2.6.1 | Molecular methods for mutation detection | 50 |
| 2.6.2 | Methods for methylation detection | 52 |
| CHAPTER 3 METHODOLOGY..... | | 54 |
| 3.1 | Overview of the study | 54 |
| 3.2 | Meta-analysis | 55 |
| 3.2.1 | Background of the study | 55 |
| 3.2.2 | Study design..... | 55 |
| 3.2.3 | Materials..... | 55 |
| 3.2.3(a) | Computer applications, programmes and software | 55 |
| 3.2.4 | Methods..... | 56 |
| 3.2.4(a) | Data sources and search..... | 56 |
| 3.2.4(b) | Study selection..... | 57 |
| 3.2.4(c) | Data extraction..... | 58 |
| 3.2.4(d) | Quality assessment..... | 58 |
| 3.2.4(e) | Publication bias identification | 59 |

| | | |
|-----|---|----|
| | 3.2.4(f) Data synthesis and sensitivity analysis | 59 |
| 3.3 | Mutational analysis | 60 |
| | 3.3.1 Background of the study | 60 |
| | 3.3.2 Study design | 60 |
| | 3.3.3 Sampling..... | 60 |
| | 3.3.3(a) Sampling population..... | 60 |
| | 3.3.3(b) Sampling frame..... | 61 |
| | 3.3.3(c) Sampling method..... | 61 |
| | 3.3.3(d) Sampling size estimation | 62 |
| | 3.3.4 Ethical approval..... | 63 |
| | 3.3.5 Materials..... | 63 |
| | 3.3.5(a) DNA samples..... | 63 |
| | 3.3.5(b) Primers for PCR..... | 64 |
| | 3.3.5(c) Chemicals and reagents | 70 |
| | 3.3.5(d) Kits and consumables | 70 |
| | 3.3.5(e) General buffers and stock solutions..... | 71 |
| | 3.3.5(f) Instruments | 72 |
| | 3.3.5(g) Computer applications, programmes and software | 73 |
| | 3.3.6 Methods..... | 74 |
| | 3.3.6(a) DNA sample preparation | 74 |
| | 3.3.6(b) Primer design for PCR..... | 76 |
| | 3.3.6(c) Polymerase chain reaction (PCR)..... | 76 |
| | 3.3.6(d) Agarose gel electrophoresis..... | 78 |
| | 3.3.6(e) PCR product clean-up..... | 79 |
| | 3.3.6(f) DNA sequencing..... | 81 |
| | 3.3.6(g) Statistical analysis..... | 81 |
| 3.4 | Methylation analysis | 83 |

| | | |
|--|---|------------|
| 3.4.1 | Background of the study | 83 |
| 3.4.2 | Study design | 83 |
| 3.4.3 | Sampling..... | 83 |
| 3.4.4 | Ethical approval..... | 83 |
| 3.4.5 | Materials..... | 83 |
| 3.4.5(a) | DNA samples..... | 83 |
| 3.4.5(b) | Primers for pyrosequencing..... | 84 |
| 3.4.5(c) | Primers for MS-PCR..... | 89 |
| 3.4.5(d) | Chemicals and reagents | 91 |
| 3.4.5(e) | Kits and consumables | 92 |
| 3.4.5(f) | General buffers and stock solutions..... | 93 |
| 3.4.5(g) | Instruments | 94 |
| 3.4.5(h) | Computer applications, programmes and software | 95 |
| 3.4.6 | Methods..... | 95 |
| 3.4.6(a) | DNA sample preparation | 95 |
| 3.4.6(b) | Primer design | 96 |
| 3.4.6(c) | Bisulfite conversion | 98 |
| 3.4.6(d) | Polymerase chain reaction (PCR)..... | 99 |
| 3.4.6(e) | Agarose gel electrophoresis..... | 101 |
| 3.4.6(f) | Pyrosequencing..... | 102 |
| 3.4.6(g) | Methylation-specific polymerase chain reaction (MS-PCR)..... | 108 |
| CHAPTER 4 RESULTS (META-ANALYSIS) | | 110 |
| 4.1 | Study selection | 110 |
| 4.2 | Characteristics of included studies..... | 112 |
| 4.3 | Meta-analysis | 117 |
| 4.4 | Quality assessment | 122 |
| 4.5 | Publication bias | 124 |

| | | |
|--|--|------------|
| 4.6 | Sensitivity analyses | 124 |
| CHAPTER 5 RESULTS (MUTATIONAL ANALYSIS)..... | | 128 |
| 5.1 | Patient characteristics | 128 |
| 5.2 | Mutational profile of the study | 129 |
| 5.3 | <i>JAK2</i> V617F and sequencing result of <i>JAK2</i> exon 12 | 133 |
| 5.3.1 | Mutational status of <i>JAK2</i> V617F in <i>BCR-ABL</i> -negative MPN .. | 133 |
| 5.3.2 | Mutational status of <i>JAK2</i> V617F in MDS/MPN | 136 |
| 5.3.3 | Mutational status of <i>JAK2</i> exon 12 in <i>BCR-ABL</i> -negative MPN | 136 |
| 5.3.4 | Mutational status of <i>JAK2</i> exon 12 in MDS/MPN..... | 164 |
| 5.4 | <i>TET2</i> sequencing result | 165 |
| 5.4.1 | Mutational status of the <i>TET2</i> gene in <i>BCR-ABL</i> -negative MPN | 165 |
| 5.4.2 | Mutational status of the <i>TET2</i> gene in MDS/MPN | 165 |
| 5.5 | <i>MyD88</i> sequencing result | 166 |
| 5.5.1 | Mutational status of the <i>MyD88</i> gene in <i>BCR-ABL</i> -negative MPN | 166 |
| 5.5.2 | Mutational status of the <i>MyD88</i> gene in MDS/MPN..... | 171 |
| CHAPTER 6 RESULTS (METHYLATION ANALYSIS)..... | | 172 |
| 6.1 | Patient characteristics | 172 |
| 6.2 | Methylation profile of the study | 172 |
| 6.3 | <i>SOCS3</i> pyrosequencing result | 176 |
| 6.3.1 | Methylation status of <i>SOCS3</i> gene promoter in <i>BCR-ABL</i> - negative MPN..... | 176 |
| 6.3.2 | Methylation status of <i>SOCS3</i> gene in MDS/MPN | 184 |
| 6.4 | <i>INPP5D</i> pyrosequencing result..... | 185 |
| 6.4.1 | Methylation status of <i>INPP5D</i> gene promoter in <i>BCR-ABL</i> - negative MPN..... | 185 |
| 6.4.2 | Methylation status of <i>INPP5D</i> gene promoter in MDS/MPN | 193 |

| | | |
|------------------------------------|---|------------|
| 6.4.3 | Methylation status of <i>INPP5D</i> exon 26 in <i>BCR-ABL</i> -negative MPN | 193 |
| 6.4.4 | Methylation status of <i>INPP5D</i> exon 26 in MDS/MPN..... | 195 |
| 6.5 | <i>INPP5D</i> MS-PCR result..... | 196 |
| 6.5.1 | Methylation status of <i>INPP5D</i> exon 26 in <i>BCR-ABL</i> -negative MPN | 196 |
| 6.5.2 | Methylation status of <i>INPP5D</i> exon 26 in MDS/MPN..... | 197 |
| CHAPTER 7 DISCUSSIONS | | 198 |
| 7.1 | Discussions..... | 198 |
| 7.1.1 | Meta-analysis on the prevalence of <i>TET2</i> gene | 198 |
| 7.1.2 | Mutational status of JAK/STAT associated genes (<i>JAK2</i> V617F, <i>JAK2</i> exon 12 and <i>TET2</i>) and TLR adaptor gene (<i>MyD88</i>) | 200 |
| 7.1.3 | Methylation status of negative regulators of JAK/STAT (<i>SOCS3</i>) and TLR downstream signalling (<i>INPP5D</i>) | 205 |
| 7.2 | Strengths and limitations of the study | 208 |
| 7.2.1 | Meta-analysis on the prevalence of <i>TET2</i> gene | 208 |
| 7.2.2 | Mutational status of JAK/STAT associated genes (<i>JAK2</i> V617F, <i>JAK2</i> exon 12 and <i>TET2</i>) and TLR adaptor gene (<i>MyD88</i>) | 211 |
| 7.2.3 | Methylation status of negative regulators of JAK/STAT (<i>SOCS3</i>) and TLR downstream signalling (<i>INPP5D</i>) | 212 |
| 7.3 | Recommendations for future research..... | 212 |
| 7.3.1 | Meta-analysis on the prevalence of <i>TET2</i> gene | 212 |
| 7.3.2 | Mutational status of JAK/STAT associated genes (<i>JAK2</i> V617F, <i>JAK2</i> exon 12 and <i>TET2</i>) and TLR adaptor gene (<i>MyD88</i>) | 213 |
| 7.3.3 | Methylation status of negative regulators of JAK/STAT (<i>SOCS3</i>) and TLR downstream signalling (<i>INPP5D</i>) | 214 |
| 7.4 | Graphical summary | 215 |

| | | |
|-----------------------------|------------------------------------|------------|
| CHAPTER 8 | SUMMARY AND CONCLUSION..... | 216 |
| REFERENCES..... | | 218 |
| APPENDICES | | |
| LIST OF PUBLICATIONS | | |

LIST OF TABLES

| | | Page |
|------------|---|-------------|
| Table 2.1 | 2016 WHO diagnostic criteria for PV (Passamonti and Maffioli, 2016). | 13 |
| Table 2.2 | 2016 WHO diagnostic criteria for ET (Passamonti and Maffioli, 2016). | 15 |
| Table 2.3 | 2016 WHO diagnostic criteria for PMF (Passamonti and Maffioli, 2016). | 17 |
| Table 2.4 | 2016 WHO diagnostic criteria for CMML (Arber <i>et al.</i> , 2016)..... | 20 |
| Table 2.5 | 2016 WHO diagnostic criteria for aCML (Arber <i>et al.</i> , 2016). | 22 |
| Table 2.6 | 2016 WHO diagnostic criteria for MDS/MPN-RS-T (Arber <i>et al.</i> , 2016). | 24 |
| Table 2.7 | 2016 WHO diagnostic criteria for JMML (Arber <i>et al.</i> , 2016)..... | 26 |
| Table 2.8 | Literature about the methylation of the <i>SOCS3</i> gene in <i>BCR-ABL</i> -negative MPN. | 40 |
| Table 2.9 | Literature about the methylation of the <i>SOCS3</i> gene in MDS/MPN. | 41 |
| Table 2.10 | Molecular methods for mutation detection. | 50 |
| Table 2.11 | Methods for methylation detection. | 52 |
| Table 3.1 | List of computer applications, programmes and software. | 56 |
| Table 3.2 | Search strategies..... | 57 |
| Table 3.3 | Quality scores of articles..... | 58 |
| Table 3.4 | Primers for <i>JAK2</i> exon 12 (dos Santos <i>et al.</i> , 2014)..... | 64 |
| Table 3.5 | Primers for <i>TET2</i> exon 1..... | 65 |
| Table 3.6 | Primers for <i>TET2</i> exon 7..... | 66 |
| Table 3.7 | Primers for <i>MyD88</i> exon 3..... | 67 |

| | | |
|------------|---|-----|
| Table 3.8 | Primers for <i>MyD88</i> exon 4..... | 68 |
| Table 3.9 | Primers for <i>MyD88</i> exon 5..... | 69 |
| Table 3.10 | List of chemicals and reagents..... | 70 |
| Table 3.11 | List of kits and consumables..... | 70 |
| Table 3.12 | List of instruments and machines..... | 72 |
| Table 3.13 | List of computer applications, programmes and software..... | 73 |
| Table 3.14 | DNA concentration of patient samples..... | 75 |
| Table 3.15 | PCR master mix..... | 77 |
| Table 3.16 | PCR cycling condition..... | 77 |
| Table 3.17 | PCR annealing temperature for different genes..... | 77 |
| Table 3.18 | Components of Wizard SV Gel and PCR Clean-Up System for 250 preps..... | 79 |
| Table 3.19 | Primers for <i>SOCS3</i> promoter..... | 85 |
| Table 3.20 | Primers for <i>INPP5D</i> promoter..... | 87 |
| Table 3.21 | Primers details of <i>INPP5D</i> exon 26..... | 88 |
| Table 3.22 | Primers for <i>INPP5D</i> exon 26..... | 89 |
| Table 3.23 | Primers for <i>INPP5D</i> exon 26..... | 90 |
| Table 3.24 | List of chemicals and reagents..... | 91 |
| Table 3.25 | List of kits and consumables..... | 92 |
| Table 3.26 | List of instruments and machines..... | 94 |
| Table 3.27 | List of computer applications, programmes and software..... | 95 |
| Table 3.28 | PCR cycling condition..... | 99 |
| Table 3.29 | PCR master mix..... | 100 |
| Table 3.30 | PCR cycling condition..... | 100 |
| Table 3.31 | DNA immobilization components..... | 104 |
| Table 3.32 | Reagents and solutions added in each through..... | 105 |

| | | |
|------------|--|-----|
| Table 3.33 | PCR master mix. | 109 |
| Table 3.34 | PCR cycling condition. | 109 |
| Table 4.1 | Major characteristics of the 35 included studies for meta-analysis. | 113 |
| Table 4.2 | Pooled prevalence of <i>TET2</i> gene mutations in different subgroups of <i>BCR-ABL</i> -negative MPN. | 119 |
| Table 4.3 | Quality assessment of the included cross-sectional studies. | 122 |
| Table 4.4 | Quality assessment of the included case-control studies. | 123 |
| Table 4.5 | Sensitivity analyses. | 125 |
| Table 5.1 | Clinical and haematological features in patients with <i>BCR-ABL</i> -negative MPN (PV, ET and MF) (n=48). | 130 |
| Table 5.2 | Clinical and haematological features in patients with MF subgroups (PMF and post-PV MF) (n=15) and MDS/MPN (n=6). .. | 131 |
| Table 5.3 | Overall mutation results in patients with <i>BCR-ABL</i> -negative MPN (n=48) and MDS/MPN (n=6). | 132 |
| Table 5.4 | Clinical and haematological features in <i>JAK2</i> V617F-positive and <i>JAK2</i> V617F-negative <i>BCR-ABL</i> -negative MPN patients (n=48)... | 134 |
| Table 5.5 | Clinical and haematological features in <i>JAK2</i> V617F-positive and <i>JAK2</i> V617F-negative PMF patients (n=11) and MDS/MPN patients (n=6). | 135 |
| Table 5.6 | Clinical and haematological features in <i>JAK2</i> exon 12-positive and <i>JAK2</i> exon 12-negative <i>BCR-ABL</i> -negative MPN patients (n=46). | 138 |
| Table 5.7 | <i>JAK2</i> exon 12 variants detected in normal control and PV (1st PCR). | 139 |
| Table 5.8 | <i>JAK2</i> exon 12 variants detected in ET and MF (1 st PCR). | 140 |
| Table 5.9 | Comparison of detected <i>JAK2</i> exon 12 variants between 1 st and 2 nd PCR in PV, ET and MF. | 141 |
| Table 5.10 | The allele and amino acid alignment of wild-type and detected <i>JAK2</i> exon 12 variants. | 142 |

| | | |
|------------|--|-----|
| Table 5.11 | Clinical and haematological features in <i>MyD88</i> -positive and <i>MyD88</i> -negative <i>BCR-ABL</i> -negative MPN patients (PV and ET) (n=33)..... | 167 |
| Table 6.1 | Clinical and haematological features in patients with <i>BCR-ABL</i> -negative MPN (PV, ET and MF) (n=45). | 173 |
| Table 6.2 | Clinical and haematological features in patients with MF subgroups (PMF and post-PV MF) (n=12) and MDS/MPN (n=3).. | 174 |
| Table 6.3 | Overall methylation results in patients with <i>BCR-ABL</i> -negative MPN and MDS/MPN..... | 175 |
| Table 6.4 | Clinical and haematological features in <i>SOCS3</i> promoter-methylated and <i>SOCS3</i> promoter-non-methylated negative <i>BCR-ABL</i> -negative MPN patients (n=45)..... | 177 |
| Table 6.5 | Clinical and haematological features in <i>SOCS3</i> promoter-methylated and <i>SOCS3</i> promoter-non-methylated patients with PMF (n=8) and patients with MDS/MPN (n=3). | 178 |
| Table 6.6 | Methylation level of <i>SOCS3</i> promoter in normal control and PV. .. | 179 |
| Table 6.7 | Methylation level of <i>SOCS3</i> promoter in ET, MF and MDS/MPN. | 180 |
| Table 6.8 | Clinical and haematological features in <i>INPP5D</i> promoter-methylated and <i>INPP5D</i> promoter-non-methylated negative <i>BCR-ABL</i> -negative MPN patients (n=45)..... | 186 |
| Table 6.9 | Clinical and haematological features in <i>INPP5D</i> promoter-methylated and <i>INPP5D</i> promoter-non-methylated patients with PMF (n=8) and patients with MDS/MPN (n=3). | 187 |
| Table 6.10 | Methylation level of <i>INPP5D</i> promoter in normal control and PV. | 188 |
| Table 6.11 | Methylation level of <i>INPP5D</i> promoter in ET, MF and MDS/MPN. | 189 |

LIST OF FIGURES

| | Page |
|------------|---|
| Figure 2.1 | Overview of JAK/STAT signalling pathway (Meyer and Levine, 2014).28 |
| Figure 2.2 | Schematic representation of the <i>JAK2</i> gene structure. The upper part shows the gene structure of <i>JAK2</i> before transcription, whereas the lower part indicates the protein structure of JAK2 after translation with the location of the domains (Adapted from (Anelli <i>et al.</i> , 2018; Palumbo <i>et al.</i> , 2019; Recio <i>et al.</i> , 2019)).30 |
| Figure 2.3 | Schema of the <i>JAK2</i> V617F mutations in <i>BCR-ABL</i> -negative MPN (Adapted from (Skoda <i>et al.</i> , 2015)).31 |
| Figure 2.4 | Schema of the <i>JAK2</i> exon 12 mutations in <i>BCR-ABL</i> -negative MPN (Adapted from (Jatiani <i>et al.</i> , 2010)).33 |
| Figure 2.5 | Schematic representation of the <i>TET2</i> gene structure. The upper part shows the gene structure of <i>TET2</i> before transcription, whereas the lower part indicates the protein structure of TET2 after translation with the location of the domains (Adapted from (Lou <i>et al.</i> , 2019; Smith <i>et al.</i> , 2010)).34 |
| Figure 2.6 | Schema of the <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (Adapted from (Cimmino <i>et al.</i> , 2011)).36 |
| Figure 2.7 | Schema of the <i>TET2</i> gene mutations in MDS/MPN (Adapted from (Cimmino <i>et al.</i> , 2011)).37 |
| Figure 2.8 | Schematic representation of the <i>SOCS3</i> gene structure. The upper part shows the location of the CpG islands. The middle part shows the gene structure of <i>SOCS3</i> before transcription, whereas the lower part indicates the protein structure of SOCS3 after translation with the location of the domains (Adapted from (Inagaki-Ohara <i>et al.</i> , 2013; Zaorska <i>et al.</i> , 2016)).39 |

| | | |
|-------------|--|----|
| Figure 2.9 | Overview of mammalian TLR signalling pathway (O'Neill <i>et al.</i> , 2013). | 42 |
| Figure 2.10 | Schematic representation of the <i>MyD88</i> gene structure. The upper part shows the gene structure of <i>MyD88</i> before transcription, whereas the lower part indicates the protein structure of MyD88 after translation with the location of the main domains (Adapted from (Dimicoli <i>et al.</i> , 2013; Umasuthan <i>et al.</i> , 2017)). | 43 |
| Figure 2.11 | Roles of MyD88 proteins in innate immunity signalling pathways (Han, 2006). | 44 |
| Figure 2.12 | Schema of the <i>MyD88</i> gene mutations (Adapted from (Dimicoli <i>et al.</i> , 2013; Umasuthan <i>et al.</i> , 2017))...... | 46 |
| Figure 2.13 | Schematic representation of the <i>INPP5D</i> gene structure. The upper part shows the location of the CpG islands. The middle part shows the gene structure of <i>INPP5D</i> before transcription, whereas the lower part indicates the protein structure of SHIP1 after translation with the location of the domains (Adapted from (Gilby <i>et al.</i> , 2007)). | 47 |
| Figure 2.14 | Self-illustrated of the crosstalk among JAK/STAT and TLR signalling pathways based on literature review, the proteins in yellow box are the genes that are being investigated in this study (Adapted from (Cannova <i>et al.</i> , 2015; Jeong <i>et al.</i> , 2019; Sly <i>et al.</i> , 2007; Yin <i>et al.</i> , 2015))...... | 49 |
| Figure 3.1 | Flowchart of the study. a) the prevalence study of <i>TET2</i> gene mutations in patients with <i>BCR-ABL</i> -negative MPN. b) the study of the mutational status of <i>JAK2</i> , <i>TET2</i> and <i>MyD88</i> in patients with <i>BCR-ABL</i> -negative MPN and patients with MDS/MPN. c) the study of epigenetic changes in the promoter region of <i>SOCS3</i> and <i>INPP5D</i> gene and <i>INPP5D</i> exon 26 in patients with <i>BCR-ABL</i> -negative MPN and MDS/MPN. | 54 |
| Figure 3.2 | Sample size calculation for patients with PV..... | 62 |
| Figure 3.3 | Sample size calculation for patients with ET..... | 62 |

| | | |
|-------------|---|-----|
| Figure 3.4 | Sample size calculation for patients with MF. | 62 |
| Figure 3.5 | Sample size calculation for patients with MDS/MPN. | 63 |
| Figure 3.6 | Representative agarose gel result for <i>JAK2</i> (exon 12), <i>TET2</i> (exon 1 and 7) and <i>MyD88</i> (exon 3, 4 and 5)..... | 79 |
| Figure 3.7 | CpG island of <i>SOCS3</i> gene predicted by MethPrimer 2.0, China. | 84 |
| Figure 3.8 | CpG island of <i>INPP5D</i> gene predicted by MethPrimer 2.0, China. .. | 86 |
| Figure 3.9 | Location of <i>INPP5D</i> gene by Qiagen, Germany. | 88 |
| Figure 3.10 | CpG island of <i>INPP5D</i> exon 26 predicted by MethPrimer 2.0, China. | 89 |
| Figure 3.11 | Locations of <i>INPP5D</i> exon 26 for pyrosequencing and MS-PCR..... | 98 |
| Figure 3.12 | Representative agarose gel result for <i>SOCS3</i> promoter and <i>INPP5D</i> promoter. | 102 |
| Figure 3.13 | Schematic diagram of the PyroMark Q96 cartridge (viewed from the top) with A for dATP, C for dCTP, E for the enzyme, G for dGTP, S for substrate and T for dTTP (PyroMark Q96 ID user manual)..... | 103 |
| Figure 3.14 | Vacuum workstation (PyroMark Q96 ID user manual)..... | 107 |
| Figure 4.1 | PRISMA flow diagram of meta-analysis. | 111 |
| Figure 4.2 | Galbraith plot identified four outlier studies..... | 127 |
| Figure 5.1 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control without any variants and mutations..... | 144 |
| Figure 5.2 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in patients with wild-type..... | 145 |
| Figure 5.3 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV3. (Upper) normal control. (Middle) the result from 1 st time sequencing with D544N and c.1194+12G>A detected. (Lower) the result from 2 nd time sequencing with R541K, D544N and c.1194+12G>A detected. | 146 |

| | | |
|-------------|---|-----|
| Figure 5.4 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV5. (Upper) normal control. (Middle) the result from 1 st time sequencing with M532I, M535R, V536G, R541K, D544N and c.1194+12G>A detected. (Lower) the result from 2 nd time sequencing with D544N detected..... | 147 |
| Figure 5.5 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV6. (Upper) normal control. (Middle) the result from 1 st time sequencing with D544N detected. (Lower) the result from 2 nd time sequencing with no mutation and variant detected. | 148 |
| Figure 5.6 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV7. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1194+12G>A detected. (Lower) the result from 2 nd time sequencing with M535R, V536G, R541K, D544N and c.1194+12G>A detected. | 149 |
| Figure 5.7 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV8. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1194+12G>A detected. (Lower) the result from 2 nd time sequencing with M535R, R541K and c.1194+12G>A detected. | 150 |
| Figure 5.8 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV11. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1194+12G>A detected. (Lower) the result from 2 nd time sequencing with M535R and c.1194+12G>A detected. | 151 |
| Figure 5.9 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV12. (Upper) normal control. (Middle) the result from 1 st time sequencing with D544N detected. (Lower) the result from 2 nd time sequencing with c.1194+12G>A detected. | 152 |
| Figure 5.10 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV15. (Upper) normal control. (Middle) the result from 1st time sequencing with c.1194+12G>A detected. (Lower) no sample was available for a 2nd time sequencing..... | 153 |

| | | |
|-------------|---|-----|
| Figure 5.11 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PV16. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1194+12G>A detected. (Lower) no sample was available for a 2 nd time sequencing. | 154 |
| Figure 5.12 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in ET9. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1194+12G>A detected. (Lower) the result from 2 nd time sequencing with c.1194+12G>A detected. | 155 |
| Figure 5.13 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in ET12. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1157delT and c.1160delT detected. (Lower) the result from 2 nd time sequencing with R541K, D544N and c.1194+12G>A detected. | 156 |
| Figure 5.14 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in ET13. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1157delT and c.1160delT detected. (Lower) the result from 2 nd time sequencing with c.1194+12G>A detected. | 157 |
| Figure 5.15 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in PMF10. (Upper) normal control. (Middle) the result from 1 st time sequencing with c.1157delT and c.1160delT detected. (Lower) the result from 2 nd time sequencing with c.1194+12G>A detected. | 158 |
| Figure 5.16 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control. (Upper) normal control. (Middle) normal control forward strand with D544N and c.1194+12G>A detected. (Lower) normal control reverse strand. | 159 |
| Figure 5.17 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control. (Upper) normal control. (Middle) normal control forward strand with c.1194+12G>A detected. (Lower) normal control reverse strand. | 160 |
| Figure 5.18 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control. (Upper) normal control. (Middle) normal control | |

| | | |
|-------------|--|-----|
| | forward strand with R541K and c.1194+12G>A detected. (Lower) normal control reverse strand..... | 161 |
| Figure 5.19 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control. (Upper) normal control. (Middle) normal control forward strand with V536G, R541K, D544N and c.1194+12G>A detected. (Lower) normal control reverse strand. | 162 |
| Figure 5.20 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control. (Upper) normal control. (Middle) normal control forward strand with M535R and c.1194+12G>A detected. (Lower) normal control reverse strand..... | 163 |
| Figure 5.21 | Sequencing results of <i>JAK2</i> exon 12 [GenBank: NG_009904.1] in normal control. (Upper) normal control. (Middle) normal control forward strand with R541K, D544N and c.1194+12G>A detected. (Lower) normal control reverse strand..... | 164 |
| Figure 5.22 | Sequencing results of <i>MyD88</i> gene [GenBank: NG_016964.1] in normal control. | 168 |
| Figure 5.23 | Sequencing results of <i>MyD88</i> gene [GenBank: NG_016964.1]. (Upper) normal control. (Lower) wild-type. | 168 |
| Figure 5.24 | Sequencing results of <i>MyD88</i> gene [GenBank: NG_016964.1] in PV6. (Upper) normal control. (Lower) the result with rs4988457 detected. | 169 |
| Figure 5.25 | Sequencing results of <i>MyD88</i> gene [GenBank: NG_016964.1] in PV11. (Upper) normal control. (Lower) the result with rs4988457 detected. | 170 |
| Figure 5.26 | Sequencing results of <i>MyD88</i> gene [GenBank: NG_016964.1] in ET8. (Upper) normal control. (Lower) the result with rs4988457 detected. | 171 |
| Figure 6.1 | Pyrogram of <i>SOCS3</i> promoter in controls. (Upper) no template control. (Middle) positive control (methylated). (Lower) negative control (non-methylated)..... | 181 |

| | | |
|------------|--|-----|
| Figure 6.2 | Pyrogram of <i>SOCS3</i> promoter in normal controls. (Upper) normal control (methylated). (Lower) normal control (non-methylated). ... | 182 |
| Figure 6.3 | Pyrogram of <i>SOCS3</i> promoter in normal controls. (Upper) patient sample (methylated). (Lower) patient sample (non-methylated)..... | 183 |
| Figure 6.4 | Pyrogram of <i>INPP5D</i> promoter in controls. (Upper) no template control. (Middle) positive control (methylated). (Lower) negative control (non-methylated)..... | 190 |
| Figure 6.5 | Pyrogram of <i>INPP5D</i> promoter in normal controls. (Upper) normal control (methylated). (Lower) normal control (non-methylated)..... | 191 |
| Figure 6.6 | Pyrogram of <i>INPP5D</i> promoter in normal controls. (Upper) patient sample (methylated). (Lower) patient sample (non-methylated)..... | 192 |
| Figure 6.7 | Pyrogram of <i>INPP5D</i> exon 26 in controls. (Upper) positive control (methylated). (Lower) negative control (non-methylated)..... | 194 |
| Figure 6.8 | Pyrogram of <i>INPP5D</i> exon 26 in normal control and patient sample. (Upper) normal control (methylated). (Lower) patient sample (non-methylated)..... | 195 |
| Figure 6.9 | MS-PCR results of <i>INPP5D</i> exon 26. a) normal control (methylated). b-d) PV (methylated). d-e) ET (methylated). f) PMF (methylated). f-g) post-PV MF (methylated). g) MDS/MPN (methylated). | 197 |
| Figure 7.1 | Graphical summary of the study. (Upper) Normal signalling pathways. (Lower) Mutated signalling pathways and their possible effects. | 215 |

LIST OF ABBREVIATIONS

| | |
|-----------------|--|
| 5-caC | 5-carboxylcytosine |
| 5-fC | 5-formylcytosine |
| 5-hmC | 5-hydroxymethylcytosine |
| 5-mC | 5-methylcytosine |
| ABL1 | ABL proto-oncogene 1 |
| aCML | Atypical chronic myeloid leukaemia |
| Akt | Protein kinase B |
| AFLP | Amplification fragment length polymorphism |
| AML | Acute myelogenous leukaemia |
| AS-PCR | Allele-specific PCR |
| ASXL1 | Additional sex combs like-1 |
| BCR-ABL | Philadelphia chromosome |
| BM | Bone marrow |
| CALCA | Calcitonin related polypeptide alpha |
| CALR | Calreticulin |
| CBL | Casitas B-lineage lymphoma |
| CCM | Chemical cleavage of mismatch |
| CD | Cys-rich domain |
| CEBPA | CCAAT/enhancer-binding protein alpha |
| CFU-GM | Granulocyte-macrophage progenitors |
| CH ₃ | Methyl group |
| CI | Confidence interval |
| CML | Chronic myelogenous leukaemia |
| CMML | Chronic myelomonocytic leukaemia |
| CNL | Chronic neutrophilic leukaemia |
| CpG | Cytosine-phosphate guanine |
| CSF3R | Colony-stimulating factor 3 receptor |
| CSGE | Conformation sensitive gel electrophoresis |
| CXCR4 | C-X-C motif chemokine receptor 4 |
| DAMP | Damage-associated molecules patterns |
| dC | Deoxycytidine |

| | |
|---------|--|
| DD | Death domain |
| ddNTPs | Dideoxynucleotide triphosphates |
| DGGE | Denaturing gradient gel electrophoresis |
| DNA | Deoxyribonucleic acid |
| DNMT3A | DNA methyltransferase 3 alpha |
| dNTPs | Deoxynucleotide triphosphates |
| DSBH | Double-stranded helix |
| ELISA | Enzyme-linked immunosorbent assay |
| EPO | Erythropoietin |
| ET | Essential thrombocythaemia |
| ETNK1 | Ethanolamine kinase 1 |
| EZH2 | Enhancer of zeste homolog 2 |
| FERM | N-terminal Band 4.1, ezrin, radixin, moesin domain |
| FGFR1 | Fibroblast growth factor receptor 1 |
| FLT3 | Fms-like tyrosine kinase 3 |
| G | Guanine |
| GM-CSF | Granulocyte macrophage-colony stimulating factor |
| Hb | Haemoglobin |
| HPLC-UV | High performance liquid chromatography-ultraviolet |
| HRM | High-resolution melt |
| HSC | Haematopoietic stem cell |
| HxD | His-x-Asp |
| IDH1 | Isocitrate dehydrogenase 1 |
| IDH2 | Isocitrate dehydrogenase 2 |
| IFN | Interferon |
| IgG | Immunoglobulin G |
| IKZF1 | IKAROS |
| INFORMM | Institute for Research in Molecular Medicine |
| INPP5D | Inositol polyphosphate 5-phosphatase D |
| IL | Interleukin |
| IL-1R | Interleukin-1 receptor |
| IRAK | Interleukin-1 receptor-associated kinase |
| IRF | Interferon regulatory factor |
| JAK2 | Janus kinase 2 |

| | |
|------------------|---|
| JPEM | The Human Research Ethics Committee of USM |
| JH | JAK homology |
| JMML | Juvenile myelomonocytic leukaemia |
| KIR | Kinase inhibitory region |
| KIT | KIT Proto-oncogene, receptor tyrosine kinase |
| KRAS | Kirsten rat sarcoma viral oncogene homolog |
| LC-MS/MS | Liquid chromatography coupled with tandem mass spectrometry |
| lncRNA | Long non-coding RNA |
| LUMA | Luminometric methylation assay |
| MAPK | Mitogen-activated protein kinase |
| MDS | Myelodysplastic syndrome |
| MDS/MPN | Myelodysplastic syndrome/myeloproliferative neoplasms syndromes |
| MDS/MPN- RS-T | MDS/MPN with ring sideroblasts and thrombocytosis |
| MDS/MPN- U | MDS/MPN-unclassifiable |
| MF | Myelofibrosis |
| MPL | Thrombopoietin receptor |
| MPN | Myeloproliferative neoplasms |
| MLL | Lysine Methyltransferase 2A |
| MLPA | Multiplex ligation-dependent probe amplification |
| mRNA | Messenger RNA |
| MS-PCR | Methylation-specific polymerase chain reaction |
| MyD88 | Myeloid differentiation primary response 88 |
| ncRNA | Non-coding RNA |
| NGS | Next-generation sequencing |
| NF- κ B | Nuclear factor-kappa B |
| NF1 | Neurofibromatosis type 1 |
| NPM1 | Nucleophosmin 1 |
| NRAS | Neuroblastoma RAS viral oncogene homolog |
| OLA | Oligonucleotide ligation assay |
| PAMP | Pathogen-associated molecular patterns |
| PCM1 | Pericentriolar material 1 |
| PCR | Polymerase chain reaction |
| PDGFRA | Platelet-derived growth factor receptor alpha |
| PDGFRB | Platelet-derived growth factor receptor beta |

| | |
|---------------|---|
| PI3K/Akt | Phosphatidylinositol 3-kinase/protein kinase B |
| PI3K | Phosphatidylinositol 3-kinase |
| piRNA | Piwi-interacting RNA |
| PMF | Primary myelofibrosis |
| PPT | Protein truncation test |
| PRMT5 | Protein arginine methyltransferase 5 |
| PRR | Pattern-recognition receptors |
| PRV1 | Polycythemia rubra vera 1 |
| PTPN6 | Protein tyrosine phosphatase non-receptor type 6 |
| PTPN11 | Protein tyrosine phosphatase non-receptor type 11 |
| PV | Polycythaemia vera |
| PVSG | Polycythemia Vera Study Group |
| RAR β 2 | Retinoic acid receptor beta 2 |
| RARA | Retinoic acid receptor alpha |
| RARS-T | Refractory anaemia with ring sideroblasts associated with marked thrombocytosis |
| RAS | Ras-GTPase |
| RBC | Red blood cell |
| RFLP | Restriction fragment length polymorphism |
| RNA | Ribonucleic acid |
| RT-PCR | Reverse transcriptase PCR |
| RUI | Research University Grants |
| SETBP1 | SET binding protein 1 |
| SF3B1 | Splicing factor 3b subunit 1 |
| SFRP2 | Secreted frizzled-related protein 2 |
| SH2 | Src homology 2 |
| SHIP1 | Inositol polyphosphate 5-phosphatase D |
| siRNA | Short interfering RNA |
| SMF | Secondary myelofibrosis |
| SNP | Single nucleotide polymorphisms |
| SOCS | Suppressor of cytokine signalling |
| SOCS1 | Suppressor of cytokine signalling 1 |
| SOCS3 | Suppressor of cytokine signalling 3 |
| SSCP | Single strand conformational polymorphism |
| SRSF2 | Serine and arginine-rich splicing factor 2 |

| | |
|--------------|--|
| STAT | Signal transducers and activators of transcription |
| T | Thymine |
| TBE | Tris-Borate-EDTA |
| TE | Tris-EDTA |
| TET2 | Ten-eleven translocation 2 |
| TIR | Toll/interleukin-1 receptor |
| TGF- β | Transforming growth factor-beta |
| TLR | Toll-like receptors |
| TP53 | Tumour protein p53 |
| TPO | Thrombopoietin |
| TRAF | Tumour necrosis factor receptor-associated factor |
| TRAM | TRIF-related adaptor molecule |
| TRIF | TIR-domain-containing adapter-inducing interferon-beta |
| TSS | Transcription start site |
| USM | Universiti Sains Malaysia |
| WBC | White blood cell |
| WES | Whole exome sequencing |
| WGBS | Whole genome bisulfite sequencing |
| WGS | Whole-genome sequencing |
| WHO | World Health Organization |
| WIF1 | WNT inhibitory factor 1 |
| WM | Waldenström Macroglobulinaemia |
| | |
| x g | Acceleration due to gravity |
| bp | Base pair |
| kb | DNA size |
| kDa | Protein size |
| ng | Nanogram |
| RLU | Relative light units |
| rpm | Revolutions per minute |
| μ g | Microgram |
| μ l | Microlitre |
| μ M | Micromolar |

LIST OF APPENDICES

| | |
|------------|---|
| Appendix A | Ethical approval letter |
| Appendix B | Prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (overall) |
| Appendix C | Prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (continents) |
| Appendix D | Prevalence of <i>TET2</i> gene mutations in PV (continents) |
| Appendix E | Prevalence of <i>TET2</i> gene mutations in ET (continents) |
| Appendix F | Prevalence of <i>TET2</i> gene mutations in MF (continents) |
| Appendix G | Prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (countries) |
| Appendix H | Prevalence of <i>TET2</i> gene mutations in PV (countries) |
| Appendix I | Prevalence of <i>TET2</i> gene mutations in ET (countries) |
| Appendix J | Prevalence of <i>TET2</i> gene mutations in MF (countries) |
| Appendix K | Prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (with or without WHO criteria) |
| Appendix L | Prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (WHO criteria) |
| Appendix M | Prevalence of <i>TET2</i> gene mutations in PV (WHO criteria) |
| Appendix N | Prevalence of <i>TET2</i> gene mutations in ET (WHO criteria) |
| Appendix O | Prevalence of <i>TET2</i> gene mutations in MF (WHO criteria) |
| Appendix P | Prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN (methods) |
| Appendix Q | Prevalence of <i>TET2</i> gene mutations in PV (methods) |
| Appendix R | Prevalence of <i>TET2</i> gene mutations in ET (methods) |
| Appendix S | Prevalence of <i>TET2</i> gene mutations in MF (methods) |
| Appendix T | Prevalence of <i>TET2</i> gene mutations in subgroups of MF |
| Appendix U | Funnel plots estimating the prevalence of <i>TET2</i> gene mutations in <i>BCR-ABL</i> -negative MPN |
| Appendix V | Prevalence of <i>TET2</i> gene mutations excluding small studies |
| Appendix W | Prevalence of <i>TET2</i> gene mutations excluding low- and moderate-quality studies |
| Appendix X | Prevalence of <i>TET2</i> gene mutations excluding outlier studies |

**ANALISIS ABERASI GEN DAN PEMETILAN PADA ISYARAT
HILIRAN JAK/STAT DAN RESEPTOR TOLL-LIKE DALAM *BCR-ABL*-
NEGATIVE MYELOPROLIFERATIVE NEOPLASMS DAN
MYELOYDYSPLASTIC SYNDROME/MYELOPROLIFERATIVE
NEOPLASMS OVERLAP SYNDROMES**

ABSTRAK

BCR-ABL-negative myeloproliferative neoplasms (MPN) dan myelodysplastic syndrome/myeloproliferative neoplasms overlap syndromes (MDS/MPN) adalah kemalignanan myeloid hasil daripada kejadian mutasi dalam genetik, epigenetik dan kromosom, terutamanya dalam isyarat hiliran janus kinase/signal transducers dan activators of transcription (JAK/STAT) dan reseptor toll-like (TLR). Kajian ini adalah untuk mengenal pasti prevalens, status mutasi gen *JAK2*, *TET2* dan *MyD88* dan profil pemetilan gen *SOCS3* dan *INPP5D* dalam kedua-dua penyakit tersebut. Mutasi dalam gen *TET2* dalam *BCR-ABL*-negative MPN telah dipilih untuk menjalankan analisis meta. Arkib sampel DNA pesakit telah digunakan untuk kajian mutasi dan kajian pemetilan. Status mutasi untuk gen *JAK2*, *TET2* dan *MyD88* dalam *BCR-ABL*-negative MPN dan MDS/MPN telah dikaji dengan penjujukan langsung. Profil pemetilan untuk kawasan promoter gen *SOCS3* dan *INPP5D* telah dikaji dengan menggunakan pyrosequencing dan exon 26 gen *INPP5D* telah dianalisis dengan menggunakan PCR pemetilan spesifik. Kawalan normal telah digunakan. Dianggarkan prevalens mutasi gen *TET2* dalam *BCR-ABL*-negative MPN adalah 15.5%. Mutasi *JAK2* V617F, lima varian missense (M532I, M535R, V536G, R541K dan D544N), satu polimorfisme nukleotida tunggal (SNP) intronik yang baru (c.1194+12G>A) dan dua deletan (c.1157delT dan c.1160delT) dalam exon 12 *JAK2* serta satu SNP intronik (rs4988457)

dalam *MyD88* berjaya dikesan. Mutasi *JAK2* V617F kerap dikesan dalam *BCR-ABL*-negative MPN (85.4%) dan MDS/MPN (50.0%). Varian missense dalam exon 12 *JAK2* (27.1%) dan *MyD88* (7.3%) hanya dikesan dalam *BCR-ABL*-negative MPN. Status pemetilan kawasan promoter bagi *SOCS3*, *INPP5D* dan exon 26 *INPP5D* tidak menunjukkan perbezaan yang ketara berbanding dengan kawalan normal. Mutasi dalam gen *TET2* didapati menyumbang kepada permulaan dan perkembangan *BCR-ABL*-negative MPN. Mutasi dalam gen tersebut dipercayai berkaitan dengan trombosis, transformasi leukemia dan mutasi gen lain yang dikenal pasti dalam penyakit yang disebutkan. Namun begitu, lebih banyak kajian diperlukan. *JAK2* V617F sangat berkaitan dengan *BCR-ABL*-negative MPN dan MDS/MPN. Mutasi dalam exon 12 *JAK2* pula lebih spesifik kepada *BCR-ABL*-negative MPN dan dicadangkan untuk dibuat dalam granulosit kerana mutasi nampaknya berkumpul dalam granulosit. Kajian ekspresi untuk gen *MyD88* yang menunjukkan rs4988457 dalam kemalighanan darah juga disyorkan. Analisis status pemetilan dalam kawasan promoter gen *SOCS3* yang berhampiran dengan tempat permulaan transkripsi dicadangkan dalam *BCR-ABL*-negative MPN.

**GENE ABERRATIONS AND METHYLATION ANALYSIS OF
JAK/STAT AND TOLL-LIKE RECEPTOR DOWNSTREAM SIGNALLING
IN *BCR-ABL*-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AND
MYELOYDYSPLASTIC SYNDROME/MYELOPROLIFERATIVE
NEOPLASMS OVERLAP SYNDROMES**

ABSTRACT

BCR-ABL-negative myeloproliferative neoplasms (MPN) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) overlap syndromes are myeloid malignancies result from genetics, epigenetics and chromosomal mutational events, particularly in janus kinase/signal transducers and activators of transcription (JAK/STAT) and toll-like receptor (TLR) signalling pathway. This study was to estimate the prevalence, identify the mutational status of *JAK2*, *TET2* and *MyD88* genes, and methylation status of *SOCS3* and *INPP5D* genes in these diseases. *TET2* gene mutations in *BCR-ABL*-negative MPN was selected for a meta-analysis. The same archived DNA samples were used for mutational and methylation analysis. The mutational status of *JAK2*, *TET2* and *MyD88* genes in *BCR-ABL*-negative MPN and MDS/MPN were studied through direct sequencing. The methylation status of the promoter region for *SOCS3* and *INPP5D* genes were studied using pyrosequencing. For exon 26 of the *INPP5D* gene was analysed using methylation-specific PCR. Normal controls were included. It was estimated that the overall pooled prevalence of *TET2* gene mutations in *BCR-ABL*-negative MPN was 15.5%. *JAK2* V617F, five missense variants (M532I, M535R, V536G, R541K and D544N), one novel intronic single nucleotide polymorphisms (SNP) (c.1194+12G>A) and two novel deletions (c.1157delT and c.1160delT) in *JAK2* exon 12 and an intronic SNP in *MyD88*

(rs4988457) were detected. *JAK2* V617F was frequently found in *BCR-ABL*-negative MPN (85.4%) and MDS/MPN (50.0%). The missense variants in *JAK2* exon 12 (27.1%) and *MyD88* (7.3%) were detected in *BCR-ABL*-negative MPN only. The methylation level of *SOCS3* promoter, *INPP5D* promoter and *INPP5D* exon 26 showed no significant difference with normal controls. *TET2* gene mutations could contribute to the initiation and development of *BCR-ABL*-negative MPN. The mutations were also believed to be related to thrombosis, leukaemic transformation and had a close relationship with other gene mutations found in the disease. However, more studies were needed. *JAK2* V617F was highly associated with *BCR-ABL*-negative MPN and MDS/MPN. Mutations in *JAK2* exon 12 seemed to be specific to *BCR-ABL*-negative MPN and were suggested to be studied in granulocytes since the mutations were found in granulocytes. A study on the expression of the *MyD88* gene with rs4988457 in blood malignancies is recommended in the future. The methylation status of the *SOCS3* promoter near the transcription start site can also be analysed in *BCR-ABL*-negative MPN.

CHAPTER 1

INTRODUCTION

1.1 Introduction to the study

World Health Organization (WHO) and Polycythemia Vera Study Group (PVSG) classify myeloproliferative neoplasms (MPN) as Philadelphia chromosome (*BCR-ABL*)-negative polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) distinguish from *BCR-ABL*-positive chronic myelogenous leukaemia (CML) (Barbui *et al.*, 2018; Michiels *et al.*, 2015). *BCR-ABL*-negative MPN is a group of rare blood cancers characterized by the overproduction of erythroid, granulocytic or megakaryocytic cells. This group of blood disorders are often accompanied by thromboembolic events and transformation to acute myelogenous leukaemia (AML) or overt myelofibrosis (MF), which in turn be the major causes of death of the diseases (Skoda *et al.*, 2015).

The first discovery of a somatic mutation in the janus kinase 2 domain (*JAK2* V617F) of erythropoietin (EPO) receptor over a decade ago provides an insight into the pathogenesis, pathophysiology and molecular biology of *BCR-ABL*-negative MPN. *JAK2* V617F mutation is found in >95% in PV, 50% to 75% in ET, and 40% to 75% in PMF (Cristina *et al.*, 2018; Skoda *et al.*, 2015). *JAK2* exon 12 mutations are found to be exclusively present in PV without *JAK2* V617F mutation (Scott *et al.*, 2007). The recent identification of thrombopoietin receptor (*MPL*) and calreticulin (*CALR*) mutations bring a sense of completeness to the biological basis for *BCR-ABL*-negative MPN (Nangalia and Green, 2017). Nevertheless, despite the discovery of the three main driver mutations (*JAK2*, *MPL* and *CALR*), some patients do not demonstrate these mentioned mutations, so-called “triple-negative” *BCR-ABL*-negative MPN,

indicating that *BCR-ABL*-negative MPN is still not thoroughly understood (Spivak, 2017).

In adults, the acquisition of somatic *JAK2*, *CALR* and *MPL* mutations are normally sporadic, and only about 7% of the cases are familial *BCR-ABL*-negative MPN (Landgren *et al.*, 2008). An acquisition of any of the *BCR-ABL*-negative MPN driver mutations does not necessarily indicate the expansion of the mutated clonal to the unaffected stem cells (Hinds *et al.*, 2016). Generally, the mutations are age- and sex-dependent (Spivak *et al.*, 2014; Stein *et al.*, 2010). For instance, *JAK2* V617F mutation can occur at any age, but *BCR-ABL*-negative MPN with *JAK2* V617F is more common in those who are over 50 years old. The incidence of *BCR-ABL*-negative MPN also increases exponentially with age along with the higher frequency of *JAK2* V617F, ten-eleven translocation 2 (*TET2*), additional sex combs like-1 (*ASXL1*), DNA methyltransferase 3 alpha (*DNMT3A*) and tumour protein 53 (*TP53*) mutations (Spivak, 2017; Xie *et al.*, 2014). As for sex-dependent, there is a higher prevalence of females with *JAK2* V617F than males in PV and ET, and more males with *JAK2* V617F than females in PMF (Moliterno *et al.*, 2006). Besides, another gene myeloid differentiation primary response 88 (*MyD88*) is overexpressed in myeloid malignancies (Dimicoli *et al.*, 2013) and mutation is also detected in the gene in one ET patient with concomitant Waldenström Macroglobulinaemia (WM) (Lu *et al.*, 2020).

Aside from the three main driver mutations, another feature of *BCR-ABL*-negative MPN is aberrant DNA methylation that could contribute to the diseases (Pérez *et al.*, 2013). Abnormal DNA methylation can be caused by occurrences of gene mutations in genes that are involved in methylation. Both *TET2* and *DNMT3A* genes

encode proteins that regulate the methylation and demethylation of DNA (Mahfoudhi *et al.*, 2016; Ren *et al.*, 2018) and these genes are somehow associated with the phenotypes of *BCR-ABL*-negative MPN (Saeidi, 2016). Other than gene mutations, abnormal DNA methylation is related to ageing as well (De and Michor, 2011). Telomere shortening is one of the causes of ageing and this phenomenon is also found to be related to *BCR-ABL*-negative MPN, but its underlying mechanisms are undefined (Ruella *et al.*, 2013).

WHO announced Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) overlap syndromes as a new category of myeloid neoplasms and acute leukaemia to include chronic clonal myeloid malignancies that display both proliferative and dysplastic features but are not grouped as myelodysplastic syndrome (MDS) or MPN (Orazi and Germing, 2008). Different from *BCR-ABL*-negative MPN, the reasons giving rise to MDS/MPN can be divided into cytogenetic abnormalities and somatic mutations (Pati and Veetil, 2019). About 70% of MDS/MPN patients are detected with an abnormal karyotype (Tiu *et al.*, 2011). The common chromosomal abnormalities are aneuploidies (monosomy 7, trisomy 8 and trisomy 9), chromosomal deletions (del17q, del13q and del20q) (Delhommeau *et al.*, 2006; Foucar, 2009) and reciprocal translocation involving tyrosine kinases (fibroblast growth factor receptor 1 (*FGFR1*), platelet-derived growth factor receptor alpha (*PDGFRA*) and platelet-derived growth factor receptor beta (*PDGFRB*)) (Chase *et al.*, 2013a; Chase *et al.*, 2013b; Cools *et al.*, 2003; James *et al.*, 2005; Lierman *et al.*, 2012). The somatic mutations in MDS/MPN occur in genes that play roles in several important cellular activities, such as signal transduction, RNA splicing, DNA transcription and translation and DNA damage response (Pati and Veetil, 2019).

Besides gene mutations, the initiation and development of *BCR-ABL*-negative MPN and MDS/MPN are somehow associated with the abnormal epigenetic modifications that remodel chromatin and eventually alter the gene expression (Chim *et al.*, 2010; Zhang *et al.*, 2013). The mechanisms for epigenetic modifications include DNA methylation that covalently adds a methyl group (-CH₃) to cytosine-rich cytosine-phosphate guanine (CpG) site (Métivier *et al.*, 2008; Pérez *et al.*, 2013), post-translational modifications of histones by methylation, acetylation, ubiquitination, phosphorylation and ADP-ribosylation of glycosylation (Huang *et al.*, 2013; Zee *et al.*, 2010), and transcriptional or post-transcriptional regulation of gene expression by non-coding RNA (ncRNA). The involved ncRNA are short interfering RNA (siRNA), microRNA, long non-coding RNA (lncRNA) and piwi-interacting RNA (piRNA) (Berdasco and Esteller, 2010). Non-coding RNA can repress the translation of protein from messenger RNA (mRNA) and degrade mRNA to halt the activities of cells (Ambros, 2004).

There are two different categories of epigenetic dysregulations in *BCR-ABL*-negative MPN. The first category is the presence of somatic mutations in genes that are involved in regulating the chromatin structure. The genes involved are *JAK2* (Dawson *et al.*, 2009; Nischal *et al.*, 2010), *ASXL1*, *TET2* (Hussein *et al.*, 2010; Schaub *et al.*, 2010; Tefferi *et al.*, 2009c), *DNMT3A* (Ren *et al.*, 2018), enhancer of zeste homolog 2 (*EZH2*) (Ernst *et al.*, 2010), isocitrate dehydrogenase 1 (*IDH1*), isocitrate dehydrogenase 2 (*IDH2*) (Green and Beer, 2010; Pardanani *et al.*, 2010b; Tefferi *et al.*, 2010), *IKAROS* (*IKZF1*) (Jäger *et al.*, 2010) and protein arginine methyltransferase 5 (*PRMT5*) (Liu *et al.*, 2011). The second category involves the different methylation levels at the promoter sites of genes that regulate cellular activities like cell proliferation, cell differentiation and apoptosis. The genes involved are *ABL* proto-

oncogene 1 (*ABL1*) (Aviram *et al.*, 2003), calcitonin related polypeptide alpha (*CALCA*), C-X-C motif chemokine receptor 4 (*CXCR4*) (Bogani *et al.*, 2008), polycythaemia rubra vera 1 (*PRVI*) (Jelinek *et al.*, 2007), retinoic acid receptor beta 2 (*RARβ2*) (Jones *et al.*, 2004), secreted frizzled-related protein 2 (*SFRP2*) (Bennemann *et al.*, 2010; Mascarenhas *et al.*, 2011), suppressor of cytokine signalling 1 (*SOCS1*) (Capello *et al.*, 2008; Fernández-Mercado *et al.*, 2008), suppressor of cytokine signalling 3 (*SOCS3*) (Capello *et al.*, 2008; Fernández-Mercado *et al.*, 2008; Fourouclas *et al.*, 2008) and WNT inhibitory factor 1 (*WIF1*) (Suzuki *et al.*, 2007).

In *BCR-ABL*-negative MPN, abnormal DNA methylation may lead to defective functioning of negative regulators. *SOCS3*, a negative regulator from the suppressor of cytokine signalling proteins (SOCS) family, possess suppressive ability against normal and mutated JAK2 proteins. The suppression helps to control the proliferation of cells and inhibits tumourigenesis (Funakoshi-Tago *et al.*, 2019). *SOCS3* induces ubiquitination on JAK2 and stops the activity of the mutated JAK2 (Kershaw *et al.*, 2014). The promoter region of the *SOCS3* gene is hypermethylated in *BCR-ABL*-negative MPN (Fourouclas *et al.*, 2008; Torun *et al.*, 2013), implying the contribution of the epigenetic down-regulation of this crucial tumour suppressor in the pathogenesis of *BCR-ABL*-negative MPN (Quentmeier *et al.*, 2008). Another negative regulator encoded by the (inositol polyphosphate-5-phosphatase D) *INPP5D* gene from the TLR signalling pathway also plays role in the pathogenesis of *BCR-ABL*-negative MPN. Deficiency in the negative regulators causes dysregulated BM haematopoiesis in *BCR-ABL*-negative MPN (Helgason *et al.*, 1998).

Thus, the causes of *BCR-ABL*-negative MPN and MDS/MPN are closely associated with the abnormality in genetics and epigenetics. Five genes (*JAK2*, *TET2*, *MyD88*, *SOCS3* and *INPP5D*) are selected for this study. The first aim of the study is

to identify the prevalence of *TET2* gene mutations in *BCR-ABL*-negative MPN by meta-analysis. Prevalence studies on another gene (*JAK2*, *MyD88*, *SOCS3* and *INPP5D*) are not done because the number of existing studies for the *JAK2* gene is too large and impossible to be done in a two-year study duration with works to be completed. As for the *MyD88*, *SOCS3* and *INPP5D* genes, only very few studies are available and are not enough for a meta-analysis study. The other two aims are to determine the mutational status of *JAK2*, *TET2* and *MyD88* gene in *BCR-ABL*-negative MPN and MDS/MPN patients and to investigate the methylation status of important negative regulators (*SOCS3* and *INPP5D*) in the janus kinase/signal transducers and activators of transcription (JAK/STAT) and toll-like receptors (TLR) signalling pathway among patients with *BCR-ABL*-negative MPN and patients with MDS/MPN.

1.2 Statement of the problem

It is suggested that the main cause of *BCR-ABL*-negative MPN is somatic mutations. Around 90% of *BCR-ABL*-negative MPN patients are found to carry at least one somatic mutation, which includes *JAK2* V617F (69%), *CALR* (15%), *TET2* (12%), *ASXL1* (5%), and *DNMT3A* (5%) (Lundberg *et al.*, 2014). Recently, defective toll-like receptors (TLR) signalling pathway that lead to prolonged TLR signalling is demonstrated as a potential predisposition to acquire *BCR-ABL*-negative MPN and could contribute to the chronic inflammatory state of *BCR-ABL*-negative MPN (Lai *et al.*, 2019; Marín Oyarzún *et al.*, 2020). Mutations in the same genes are associated with MDS/MPN as well (Pati and Veetil, 2019). The association of *JAK2*, *CALR* and *MPL* with *BCR-ABL*-negative MPN are confirmed and included in the diagnosis of *BCR-ABL*-negative by WHO (Barbui *et al.*, 2018), but not the other genes. Therefore, a meta-analysis on the prevalence of *TET2* gene mutation is believed can help to reveal

the connection between *TET2* gene mutations and *BCR-ABL*-negative MPN. All currently available data are mainly from the Caucasian population, with only a few from Asian countries. So, a better understanding of the genetic changes among patients with *BCR-ABL*-negative MPN and MDS/MPN from Asian countries such as Malaysia may help to gain a more thorough insight into the prevalence, diagnosis and surveillance of *BCR-ABL*-negative MPN as well as MDS/MPN.

Epigenetic mechanisms have roles in the pathogenesis of *BCR-ABL*-negative MPN (McPherson *et al.*, 2017) and MDS/MPN (Deininger *et al.*, 2017). Aberrant DNA methylation is frequently found in MDS/MPN, such as modified epigenetic landscape in chronic myelomonocytic leukaemia (CMML) (Perez *et al.*, 2012; Yamazaki *et al.*, 2012) and hypermethylation of several genes in juvenile myelomonocytic leukaemia (JMML) (Fluhr *et al.*, 2016; Olk-Batz *et al.*, 2011; Wilhelm *et al.*, 2016). In *BCR-ABL*-negative MPN, important negative regulators are studied for their methylation status. *SOCS* family, protein tyrosine phosphatase non-receptor type 6 (*PTPN6*) and *TET2* gene are found to be methylated in the diseases (Chim *et al.*, 2010; Zhang *et al.*, 2013). There are methylation studies done on *BCR-ABL*-negative MPN and MDS/MPN, however, the number was small, with only a few studies on JAK/STAT signalling pathway and no studies on the TLR signalling pathway were available. It is believed that a better understanding of the epigenetic landscape in *BCR-ABL*-negative MPN and MDS/MPN can provide a clear picture of the role of epigenetics in the pathogenesis of diseases since the epigenetic landscape shapes the biological and clinical expression which contribute to the development of the diseases.

1.3 Research question

1. What are the DNA mutational status and methylation patterns in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN?
2. What is the prevalence of JAK/STAT associated gene (*TET2*) gene mutations in patients with *BCR-ABL*-negative MPN?
3. What are the mutational status of JAK/STAT associated genes (*JAK2* V617F, *JAK2* exon 12 and *TET2*) and TLR adaptor gene (*MyD88*) in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN?
4. What are the methylation status of negative regulators to JAK/STAT (*SOCS3*) and TLR downstream signalling (*INPP5D*) in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN?

1.4 Justification of the study

Besides the main driver mutations, *TET2* gene mutation appears to be related to *BCR-ABL*-negative MPN based on the findings of previous studies, however, there is no precise answer on how common is *TET2* gene mutation in *BCR-ABL*-negative MPN. Thus, this study is expected to gather all the data of *TET2* gene mutations in *BCR-ABL*-negative MPN and analyse the data to learn about the commonness of *TET2* gene mutations in *BCR-ABL*-negative MPN.

The genomics era has brought with it plenty of dramatic advances in our understanding of the molecular basis of diseases. Many studies have been carried out to study different kinds of diseases, but only a very small number of studies are related to *BCR-ABL*-negative MPN and MDS/MPN as compared to other myeloid malignancies. Thus, this study is expected to collect more genetic (*JAK2*, *TET2* and *MyD88*) and epigenetic information (*SOCS3* and *INPP5D*) on patients with *BCR-ABL*-

negative MPN and patients with MDS/MPN. The data collected can be used for future reference such as in assisting to find more strategic approaches to treat *BCR-ABL*-negative MPN and MDS/MPN, identifying any novel molecular prognostic marker or searching for some good candidates for gene therapy.

1.5 Hypothesis

1. There are presence of gene mutations and abnormal methylation patterns in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN patients.
2. *TET2* gene mutation is prevalent in patients with *BCR-ABL*-negative MPN.
3. There are the presence of gene mutations and/or gene polymorphisms in *JAK2*, *TET2* and *MyD88* genes in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN patients.
4. There are presence of abnormal methylation patterns in *SOCS3* and *INPP5D* genes in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN patients.

1.6 Objective of the study

1.6.1 General objective

To study the DNA mutation and methylation of JAK/STAT and TLR downstream signalling genes in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN.

1.6.2 Specific objectives

1. To estimate the prevalence of JAK/STAT associated gene (*TET2*) in patients with *BCR-ABL*-negative through meta-analysis.

2. To determine the mutational status of JAK/STAT associated genes (*JAK2* V617F, *JAK2* exon 12 and *TET2*) and TLR adaptor gene (*MyD88*) in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN patients using direct DNA sequencing.
3. To determine the methylation status of negative regulators of JAK/STAT (*SOCS3*) and TLR downstream signalling (*INPP5D*) in patients with *BCR-ABL*-negative MPN and patients with MDS/MPN using pyrosequencing and/or methylation-specific polymerase chain reaction (MS-PCR).

CHAPTER 2

LITERATURE REVIEW

2.1 Myeloproliferative neoplasms (MPN)

MPN are clonal bone marrow stem cells disorders characterised by the overproduction of erythroid, myeloid and megakaryocytic lineages (Campbell and Green, 2006). MPN consists of two categories, the *BCR-ABL*-positive CML and the *BCR-ABL*-negative MPN (Kiladjian, 2012).

2.1.1 *BCR-ABL*-negative MPN

BCR-ABL-negative MPN is a condition in which the Philadelphia chromosome involving a translocation from chromosome 22 to chromosome 9 is absent and no *BCR-ABL* fusion gene is formed (Chopra *et al.*, 1999). The three classical *BCR-ABL*-negative MPN include PV, ET and PMF (Elf, 2020). PV is defined by an increased red blood cell (RBC) mass and occasion raise in white blood cell (WBC) counts. ET is characterised by a rise in platelet counts but with normal RBC mass. PMF manifests a fibrosis condition in bone marrow (BM) (Yow *et al.*, 2020). These *BCR-ABL*-negative MPN share common features, including an increased risk of thrombosis, hypercellularity in BM, haemorrhages, and transformation to AML (Marchetti and Falanga, 2007). Patients with PV and ET have chances to develop secondary myelofibrosis (SMF) by transforming to post-PV myelofibrosis or post-ET myelofibrosis. Besides, patients with ET can subsequently develop erythrocytosis and have overlap PV and ET at the same time (Meyer and Levine, 2014).

BCR-ABL-negative MPN is closely associated with gene mutations. There are three somatic driver gene mutations (*JAK2*, *CALR*, *MPL*) in *BCR-ABL*-negative MPN. All three main driver mutations are involved in JAK/STAT signalling pathway. *JAK2* mutations are mostly found in PV, whereas *CALR* and *MPL* gene mutations are almost

exclusively present in ET and PMF. Majority of the patients with *BCR-ABL*-negative MPN carry at least one of the three driver mutations, and sometimes they can carry two of the mutations at the same time (Nangalia and Green, 2017; Tefferi and Pardanani, 2015; Ye *et al.*, 2020).

2.1.1(a) Polycythaemia vera (PV)

PV is the most common type of the three classical *BCR-ABL*-negative MPN and is characterised by the overproduction of red blood cells in the BM. The cause of PV is unclear but *JAK2* mutations are found to be associated with the disease. *JAK2* mutations lead to an excess number of RBC in patients with PV. Increased RBC causes symptoms like headache, migraine, dizziness, visual disturbances, burning pains in the extremities and weakness in limbs or face. An elevated platelet count may result in nose bleeds and easy bruising. A high WBC number tends to induce gout in patients. Occasionally, patients may suffer from the inability to eat a full meal, abdominal pain and abdominal fullness due to splenomegaly (Spivak, 2013).

For testing of PV, patients show erythrocytosis, leukocytosis, thrombocytosis and are often accompanied by splenomegaly. PV patients may experience expanded RBC numbers alone or with combinations of increased RBC, WBC or platelet numbers. Since there is a high prevalence of *JAK2* mutations in PV (95%), *JAK2* mutational test is included as a diagnostic criterion for PV. However, *JAK2* mutations are present in both ET and PMF (50%), PV can be distinguished from them by referring to the elevated RBC count in patients (Spivak, 2013).

According to the 2016 WHO classification and diagnostic criteria, patients who fulfil either all three major criteria or the first two major criteria and the minor criterion are diagnosed as PV (Table 2.1) (Passamonti and Maffioli, 2016).

Table 2.1 2016 WHO diagnostic criteria for PV (Passamonti and Maffioli, 2016).

| Major criteria | |
|----------------------------------|--|
| Criterion 1 (clinical) | |
| Hb, or | >16.5 g/dL in men, >16.0 g/dL in women |
| Haematocrit, or | >49% in men, >48% in women |
| Red cell mass | Increased 25% above mean normal predicted value |
| Criterion 2 (morphologic) | |
| BM morphology* | Hypercellularity for age with trilineage growth (panmyelosis), including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size) |
| Criterion 3 (genetic) | |
| <i>JAK2</i> V617F, or | Presence |
| <i>JAK2</i> exon 12 mutation | Presence |
| Minor criterion | |
| Serum EPO level | Subnormal |

*Criterion number 2 (BM biopsy) may not be required in cases with sustained absolute erythrocytosis: Hb levels >18.5 g/dL in men (haematocrit 55.5%) or >16.5 g/dL in women (haematocrit 49.5%) if major criterion 3 and the minor criterion are present.

2.1.1(b) Essential thrombocythaemia (ET)

ET is a type of rare blood cancer in which the body produces too many platelets. The prevalence of ET is around two per 100,000 people and is more common in the aged (>60 years old). Patients with ET have chances to transform into post-ET myelofibrosis when the BM is replaced by scarred tissues and develop into a form of leukaemia. One of the factors leading to ET is the presence of genetic changes in genes that are responsible for blood cells production. About 90% of the patients with ET are found to carry gene mutations in *JAK2*, *CALR* or *MPL* (Double and Harrison, 2015).

Around half of the patients with ET are asymptomatic. For those patients who show symptoms, the symptoms can be varied in a wide range and often include headache and fatigue. Inappropriate formation of blood clots due to an elevated number of platelets is the main problem faced by the patients. The blood clots can block arteries and veins in the body and causing thrombosis, heart attacks, stroke and pulmonary embolism. Also, a great number of platelets can introduce a ‘thick blood’ condition and affect the smoothness of blood flow. This causes headache, tiredness, night sweat, splenomegaly, visual disturbances, bone pain and burning or itching feeling in the four limbs. Bleeding problems may also occur since the clotting factors accumulate to the platelet and do not function properly. ET is more common in the aged (>60 years old), and those who have a previous history of arterial or venous thrombosis, high platelet counts and presence of cardiovascular risk factors (Double and Harrison, 2015).

According to the 2016 WHO classification and diagnostic criteria, patients who fulfil either all four major criteria or the first three major criteria and the minor criterion are diagnosed as ET (Table 2.2) (Passamonti and Maffioli, 2016).

Table 2.2 2016 WHO diagnostic criteria for ET (Passamonti and Maffioli, 2016).

| Major criteria | |
|---|---|
| Criterion 1 (clinical) | |
| Platelet count | >450 x 10 ⁹ /L |
| Criterion 2 (morphologic) | |
| BM morphology | Proliferation mainly of the megakaryocytes lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in neutrophil granulopoiesis or erythropoiesis, and very rarely minor (grade 1) increase in reticulin fibres |
| Criterion 3 (clinical) | |
| WHO criteria for <i>BCR-ABL</i> -positive CML, PV, PMF, MDS, or other myeloid neoplasms | Not meeting |
| Criterion 4 (genetic) | |
| <i>JAK2</i> , <i>CALR</i> or <i>MPL</i> mutation | Presence |
| Minor criterion | |
| Clonal marker, or | Presence |
| Reactive thrombocytosis | Absence |

2.1.1(c) Myelofibrosis

Myelofibrosis is very rare and occurs in one out of 100,000 people and is more common in the aged (>60 years old). Myelofibrosis is a type of rare blood cancer in which the spongy tissue in BM is replaced by fibrous scar tissues through a process called fibrosis. Fibrosis disrupts the normal function of BM and affects the ability of the body to produce normal blood cells. Since the BM is affected by myelofibrosis, the blood cells are made in other organs, for example, the spleen and liver. This causes

spleen enlargement by 10 to 20 folds. There are two types of myelofibrosis, primary myelofibrosis (PMF) and secondary myelofibrosis (SMF). PMF occurs in patients without any previous history of BM problem, whereas SMF is another type of myelofibrosis that occur after a prior diagnosis of other blood disorders. For the myelofibrosis that develops in patients diagnosed with PV and ET, they are called post-PV myelofibrosis and post-ET myelofibrosis respectively. About 50% of myelofibrosis patients have a mutation in the *JAK2* gene. Although the rest 50% of patients show no mutation in the *JAK2* gene, their activity of normal *JAK2* gene also shows increment as in *JAK2* gene mutated patients. Apart from that, other gene mutations are detected in patients with myelofibrosis as well (Harrison and McLornan, 2014).

For myelofibrosis patients, they may be asymptomatic during diagnosis. However, symptoms and signs can develop over time. As the disease progresses, patients with myelofibrosis may experience fever, fatigue, bleeding complications, loss of weight, sweating at night, poor appetite and bone pain. If splenomegaly develops, the patients may suffer discomfort in the abdomen or pain under the ribs at the left, particularly after meals. Sometimes, anaemia, painful joints and gout may occur (Harrison and McLornan, 2014).

According to the 2016 WHO classification and diagnostic criteria, patients who fulfil either all three major criteria and at least one minor criterion are diagnosed as PMF (Table 2.3) (Passamonti and Maffioli, 2016).

Table 2.3 2016 WHO diagnostic criteria for PMF (Passamonti and Maffioli, 2016).

| Major criteria | |
|--|---|
| Criterion 1 (morphologic) | |
| BM morphology | Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3 |
| Criterion 2 (morphologic) | |
| WHO criteria for PV, ET, <i>BCR-ABL</i> -positive CML, MDS, or other myeloid neoplasms | Not meeting |
| Criterion 3 (genetic) | |
| <i>JAK2</i> , <i>CALR</i> or <i>MPL</i> mutation, or | Presence |
| Clonal marker*, or | Presence |
| Reactive BM reticulin fibrosis** | Absence |
| Minor criterion | |
| Anaemia not attributed to a comorbid condition | Presence |
| WBC count | $\geq 11 \times 10^9/L$ |
| Spleen size | Palpable |
| Serum lactate dehydrogenase | Increased to the above upper normal limit of the institutional reference range |
| Leuko-erythroblastosis | Presence |

*In the absence of any of the 3 major clonal mutations, the search for the most frequent accompanying mutations (eg, *ASXL1*, *EZH2*, *TET2*, *IDH1/IDH2*, *SRSF2*, and *SF3B1*) are of help in determining the clonal nature of the disease.

**Minor (grade 1) reticulin fibrosis secondary to an infection, autoimmune disorder or other chronic inflammatory conditions, hairy cell leukaemia or other lymphoid neoplasms, metastatic malignancy, or toxic (chronic) myelopathies.

2.2 Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) overlap syndromes

A new MDS/MPN category was introduced in the 3rd edition of the WHO classification of myeloid neoplasms and acute leukaemia to include myeloid disorders that overlap between MDS and MPN (Orazi and Germing, 2008). In the latest 2016 version, MDS/MPN category consists of atypical chronic myeloid leukaemia (aCML), CMML, myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), JMML and MDS/MPN-unclassifiable (MDS/MPN-U) (Arber *et al.*, 2016). MDS/MPN are different from pure MDS or MPN and have their features. For example, a high percentage of monocytes in CMML, severe granulocytic dysplasia in aCML and high platelet count in MDS/MPN-RS-T. Nowadays, advanced genomic and molecular studies have improved our understanding of the pathogenesis of MDS/MPN, but there is still a lack of specific treatments for MDS/MPN. More studies and efforts are needed (Thota and Gerds, 2018).

2.2.1 Chronic myelomonocytic leukaemia (CMML)

The most common type of MDS/MPN is CMML (Srouf *et al.*, 2016). CMML is commonly seen in older individuals, shows higher prevalence in males, presents with monocytosis, hepatosplenomegaly, dysplastic changes in BM, cytopenia and risk of transformation into AML (Arber *et al.*, 2016; Saarni and Linman, 1971). Mutations in five categories are associated with CMML: epigenetic regulators, chromatin modification, DNA repair, signalling transduction and spliceosome (Gur *et al.*, 2018; Thota and Gerds, 2018). CMML can be classified into three different groups, CMML-0 (peripheral blood: <2% blasts, BM: <5% blasts), CMML-1 (peripheral blood: 2% to 4% blasts, BM: 5% to 9%) and CMML-2 (peripheral blood: 5% to 19% blasts, BM: 10% to 19% blasts) (Thota and Gerds, 2018).

The diagnosis criteria for CMML based on the 2016 WHO classification and diagnostic criteria of myeloid neoplasms are as shown in Table 2.4 (Arber *et al.*, 2016).

Table 2.4 2016 WHO diagnostic criteria for CMML (Arber *et al.*, 2016).

| CMML diagnostic criteria |
|---|
| <ul style="list-style-type: none"> • Persistent peripheral monocytosis $\geq 1 \times 10^9/L$, with monocytes accounting for $\geq 10\%$ of the WBC count • Not meeting WHO criteria for <i>BCR-ABL</i>-positive CML, PMF, PV, or ET* • No evidence of <i>PDGFRA</i>, <i>PDGFRB</i>, or <i>FGFR1</i> rearrangement or <i>PCMI-JAK2</i> (should be specifically excluded in cases with eosinophilia) • $< 20\%$ blasts in the blood and BM** • Dysplasia in 1 or more myeloid lineages. If myelodysplasia is absent or minimal, the diagnosis of CMML may still be made if the other requirements are met and • An acquired clonal cytogenetic or molecular genetic abnormality is present in hemopoietic cells*** <p>Or</p> <ul style="list-style-type: none"> • The monocytosis (as previously defined) has persisted for at least 3 months and • All other causes of monocytosis have been excluded |

*Cases of MPN can be associated with monocytosis or they can develop it during the disease. These cases may simulate CMML. In these rare instances, a previously documented history of MPN excludes CMML, whereas the presence of MPN features in the BM and/or of MPN-associated mutations (*JAK2*, *CALR*, or *MPL*) tend to support MPN with monocytosis rather than CMML.

**Blasts and blast equivalents include myeloblasts, monoblasts, and promonocytes. Promonocytes are monocytic precursors with abundant light grey or slightly basophilic cytoplasm with a few scattered, fine lilac-coloured granules, finely distributed, stippled nuclear chromatin, variably prominent nucleoli, and delicate nuclear folding or creasing. Abnormal monocytes, which can be present both in the PB and BM, are excluded from the blast count.

***The presence of mutations in genes often associated with CMML (eg, *TET2*, *SRSF2*, *ASXL1*, *SETBP1*) in the proper clinical context can be used to support a diagnosis. It should be noted, however, that many of these mutations can be age-related or be present in subclones. Therefore, caution would have to be used in the interpretation of these genetic results.

2.2.2 Atypical chronic myeloid leukaemia (aCML)

aCML is a rare subtype of MDS/MPN (Arber *et al.*, 2016) and is not related to CML but it shares some characteristics with CML. Patients with aCML are older, present with splenomegaly, granulocytosis and circulating myeloid precursors (Hernandez *et al.*, 2000; Kurzrock *et al.*, 2001; Kurzrock *et al.*, 1990; Wang *et al.*, 2014). In separating aCML from CML, a lack of *BCR-ABL* fusion gene, presence of dysgranulopoiesis and BM dysplasia can be referred (Arber *et al.*, 2016; Hernandez *et al.*, 2000; Kurzrock *et al.*, 2001; Kurzrock *et al.*, 1990; Wang *et al.*, 2014). The clinical features of aCML include organomegaly, BM failure and increased leukaemic burden (Hernandez *et al.*, 2000).

Patients with aCML tend to present with a trisomy chromosomal condition, such as trisomy 8, trisomy 13 and trisomy 21. Other than that, deletion in chromosome 20 (del(20q)) and isochromosome 17q (i(17q)) are also found in patients with aCML. Somatic mutations in SET binding protein 1 (*SETBP1*), ethanolamine kinase 1 (*ETNK1*), colony-stimulating factor 3 receptor (*CSF3R*) and ras-GTPase (*RAS*) are seen in aCML (Thota and Gerds, 2018). The three driver mutations for MPN (*JAK2*, *CALR* and *MPL*) are not found in aCML (Arber *et al.*, 2016).

The diagnosis criteria for aCML based on the 2016 WHO classification and diagnostic criteria of myeloid neoplasms are as shown in Table 2.5 (Arber *et al.*, 2016).

Table 2.5 2016 WHO diagnostic criteria for aCML (Arber *et al.*, 2016).

aCML diagnostic criteria

- Peripheral leukocytosis due to increased numbers of neutrophils and their precursors (promyelocytes, myelocytes, metamyelocytes) comprising $\geq 10\%$ of leukocytes)
- Dysgranulopoiesis, which may include abnormal chromatin clumping
- No or minimal absolute basophilia; basophils usually $< 2\%$ of leukocytes
- No or minimal absolute monocytosis; monocytes $< 10\%$ of leukocytes
- Hypercellular BM with granulocytic proliferation and granulocytic dysplasia, with or without dysplasia in the erythroid and megakaryocytic lineages
- $< 20\%$ blasts in the blood and BM
- No evidence of *PDGFRA*, *PDGFRB*, or *FGFR1* rearrangement, or *PCMI-JAK2*
- Not meeting WHO criteria for *BCR-ABL*-positive CML, PMF, PV, or ET*

*Cases of MPN, particularly those in accelerated phase and/or in post-PV or post-ET myelofibrosis, if neutrophilic, may simulate aCML. A previous history of MPN, the presence of MPN features in the BM and/or MPN-associated mutations (in *JAK2*, *CALR*, or *MPL*) tend to exclude a diagnosis of aCML. Conversely, a diagnosis of aCML is supported by the presence of *SETBP1* and/or *ETNK1* mutations. The presence of a *CSF3R* mutation is uncommon in aCML and if detected should prompt a careful morphologic review to exclude an alternative diagnosis of CNL or other myeloid neoplasms.

2.2.3 Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

MDS/MPN-RS-T was formerly known as refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T). Ring sideroblasts are erythroblasts in which perinuclear mitochondrion iron abnormally accumulates on the nuclear circumference of the cells (Cazzola and Invernizzi, 2011). In the 2016 revised 4th edition WHO classification, MDS/MPN-RS-T is officially listed as a new entity in MDS/MPN (Thompson *et al.*, 2021). Patients with MDS/MPN-RS-T have features of MDS with ring sideroblasts and also show persistent thrombocytosis associated with abnormal megakaryocytes resembling MPN (Patnaik and Tefferi, 2017). MDS/MPN-RS-T is found in older people, equally distributed among males and females, and present with higher haemoglobin (Hb) and high platelet counts (Broseus *et al.*, 2012; Jeromin *et al.*, 2015).

At the genetic and molecular level, a high frequency of splicing factor 3b (*SF3B1*) mutations is found in MDS/MPN-RS-T and induces abnormal erythropoiesis and the formation of ring sideroblasts. Similar to *BCR-ABL*-negative MPN, *JAK2* V617F is detected in MDS/MPN-RS-T and causes the proliferation of different lineages of blood cells in patients (Norris and Stone, 2008; Wardrop and Steensma, 2009). Both *JAK2* and *SF3B1* mutations usually co-exist at the same time (Arber *et al.*, 2016). Besides, *TET2*, *ASXL1*, *DNMT3A* and *MPL* genes are also found to be mutated in MDS/MPN-RS-T (Broseus *et al.*, 2012; Jeromin *et al.*, 2015).

The diagnosis criteria for MDS-RS-T based on the 2016 WHO classification and diagnostic criteria of myeloid neoplasms are as shown in Table 2.6 (Arber *et al.*, 2016).

Table 2.6 2016 WHO diagnostic criteria for MDS/MPN-RS-T (Arber *et al.*, 2016).

MDS/MPN-RS-T diagnostic criteria

- Anaemia associated with erythroid lineage dysplasia with or without multilineage dysplasia, $\geq 15\%$ ring sideroblasts,* $< 1\%$ blasts in peripheral and $< 5\%$ blasts in the BM
- Persistent thrombocytosis with platelet count $\geq 450 \times 10^9/L$
- Presence of a *SF3B1* mutation or, in the absence of *SF3B1* mutation, no history of recent cytotoxic or growth factor therapy that could explain the myelodysplastic/myeloproliferative features**
- No *BCR-ABL* fusion gene, no rearrangement of *PDGFRA*, *PDGFRB*, or *FGFR1*; or *PCMI-JAK2*; no (3;3)(q21;q26), inv(3)(q21q26) or del(5q)***
- No preceding history of MPN, MDS (except MDS-RS), or other types of MDS/MPN

*At least 15% ring sideroblasts required even if *SF3B1* mutation is detected.

**A diagnosis of MDS/MPN-RS-T is strongly supported by the presence of *SF3B1* mutation together with a mutation in *JAK2* V617F, *CALR*, or *MPL* genes.

***In a case that otherwise fulfils the diagnostic criteria for MDS with isolated del(5q)-no or minimal absolute basophilia; basophils usually $< 2\%$ of leukocytes.